Allogene Therapeutics Inc (NAS:ALLO)
$ 2.07 -0.01 (-0.48%) Market Cap: 432.18 Mil Enterprise Value: 137.28 Mil PE Ratio: 0 PB Ratio: 0.76 GF Score: 28/100

Allogene Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 11, 2022 / 08:45PM GMT
Release Date Price: $12.9 (+5.74%)
Cory William Kasimov
JPMorgan Chase & Co, Research Division - Senior Biotechnology Analyst

All right. Good afternoon from the 40th Annual JPMorgan Healthcare Conference. My name is Cory Kasimov. I'm a senior large cap biotech analyst here. And it's my pleasure to introduce Allogene Therapeutics and CEO, David Chang. (Operator Instructions) So with that, David, thanks as always for joining us today, and let me turn things over to you for an update on Allogene.

David D. Chang
Allogene Therapeutics, Inc. - Co-Founder, President, CEO & Director

Good afternoon, Corey, and thank you very much for having Allogene at this JPM Health Conference and Happy New Year to you all. I'm just going to move straight into the presentation. If you can just move to Slide 2. I just want to emphasize that we will be making forward-looking statements in this presentation, which are subject to risks, as stated in our SEC filing.

Moving to the next slide, in Slide 3. This slide really gives a snapshot of Allogene as we create the allogeneic South Turkey playbook. We

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot